AbbVie Inc. (ABBV)
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.
AbbVie Up More Than 30% in 6 Months: How to Play the Stock
AbbVie's 30% surge in six months is powered by booming sales of Skyrizi and Rinvoq and renewed strength across oncology and neuroscience.
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
This 3 Stocks Portfolio Provides Monthly Income
Who doesn't like payday? Investors can structure a portfolio that provides monthly income with this combination of three stocks.
Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings
ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's decline.
AbbVie: "Strong Buy" On Rinvoq Expansions And Immunology Pipeline Addition
AbbVie earns a Strong Buy rating in my book, driven by Rinvoq's label expansions and robust immunology pipeline growth. ABBV achieved FDA approval for Rinvoq in giant cell arteritis and reported strong phase 3 results for severe alopecia areata, supporting long-term revenue growth. The acquisition of Capstan Therapeutics brings CPTX2309, a first-in-class tLNP CAR-T candidate, potentially transforming B-cell autoimmune disorder treatment landscape.
AbbVie (ABBV) Stock Falls Amid Market Uptick: What Investors Need to Know
The latest trading day saw AbbVie (ABBV) settling at $226.22, representing a -1.27% change from its previous close.
Can Rinvoq and Skyrizi Sales Drive Another Strong Quarter for AbbVie?
ABBV leans on booming Skyrizi and Rinvoq-driven sales to sustain growth and counter Humira's decline as Q3 results approach.
AbbVie vs. Eli Lilly: Which Large Drugmaker Has the Edge in 2025?
Lilly's explosive GLP-1 growth and AbbVie's post-Humira rebound set up a fierce 2025 showdown between two pharma powerhouses.
Why AbbVie and Johnson & Johnson Could Outperform Pfizer
Pfizer Inc. NYSE: PFE made a strong move higher after it became the first drug manufacturer to sign on as part of the TrumpRx platform. PFE stock is up nearly 14% since its closing price of around $23.61 on Sept.
AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week?
ABBV shares rose 6% last week as optimism swept the pharma sector after Pfizer's landmark drug-pricing deal with the Trump administration.
Top Dividend Stocks Poised for Explosive Growth in 2026 (ABBV, GD, RGR)
Geopolitical events, judicial rulings, new law legislation, and policy changes are all circumstances occurring on domestic and international stages that are triggering big stock moves in various industrial sectors.
